References
1. Tan MY, Wright D, Syngelaki A, Akolekar R, Cicero S, Janga D, et al. Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2018;51(6):743-50.
2. Chappell LC, Brocklehurst P, Green ME, Hunter R, Hardy P, Juszczak E, et al. Planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial. Lancet (London, England). 2019;394(10204):1181-90.
3. National Institute for Health and Care Excellence. Hypertension in Pregnancy: Diagnosis and Management. 2019.
4. Thangaratinam S, Allotey J, Marlin N, Dodds J, Cheong-See F, von Dadelszen P, et al. Prediction of complications in early-onset pre-eclampsia (PREP): development and external multinational validation of prognostic models. BMC medicine. 2017;15(1):68.
5. von Dadelszen P, Payne B, Li J, Ansermino JM, Broughton Pipkin F, Cote AM, et al. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet (London, England). 2011;377(9761):219-27.
6. Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy hypertension. 2014;4(2):97-104.
7. Thangaratinam S, Allotey J, Marlin N, Mol BW, Von Dadelszen P, Ganzevoort W, et al. Development and validation of Prediction models for Risks of complications in Early-onset Pre-eclampsia (PREP): a prospective cohort study. Health technology assessment (Winchester, England). 2017;21(18):1-100.
8. Collins GS, Ogundimu EO, Altman DG. Sample size considerations for the external validation of a multivariable prognostic model: a resampling study. Statistics in medicine. 2016;35(2):214-26.
9. Chappell LC, Duckworth S, Seed PT, Griffin M, Myers J, Mackillop L, et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation. 2013;128(19):2121-31.
10. DW Hosmer SL. Applied Logistic Regression. 2nd Edition ed. New York, NY: John Wiley and Sons; 2000.
11. Duhig KE, Myers J, Seed PT, Sparkes J, Lowe J, Hunter RM, et al. Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial. Lancet (London, England). 2019;393(10183):1807-18.
12. Verlohren S, Herraiz I, Lapaire O, Schlembach D, Moertl M, Zeisler H, et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. American journal of obstetrics and gynecology. 2012;206(1):58.e1-8.
13. Lou WZ, Jiang F, Hu J, Chen XX, Song YN, Zhou XY, et al. Maternal Serum Angiogenic Factor sFlt-1 to PlGF Ratio in Preeclampsia: A Useful Marker for Differential Diagnosis and Prognosis Evaluation in Chinese Women. Disease markers. 2019;2019:6270187.
14. Meler E, Scazzocchio E, Peguero A, Triunfo S, Gratacos E, Figueras F. Role of maternal plasma levels of placental growth factor for the prediction of maternal complications in preeclampsia according to the gestational age at onset. Prenatal diagnosis. 2014;34(7):706-10.
Table 1: Maternal demographics and baseline characteristics at enrolment (by expectant management groups)